ArticleThe Journal of experimental medicine2016
M-CSF improves protection against bacterial and fungal infections after hematopoietic stem/progenitor cell transplantation.
Article in The Journal of experimental medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 50 citations in OpenAlex.
- Hematopoietic stem cell a reservoir of innate immune memory.Frontiers in immunology · 2024Review
- Human milk oligosaccharides regulate human macrophage polarization and activation in response toFrontiers in immunology · 2024Article
- Molecular Pathway, Epidemiological Data and Treatment Strategies of Fungal Infection (Mycoses): A Comprehensive Review.Central nervous system agents in medicinal chemistry · 2024Review
- Macrophage colony-stimulating factor as a weapon against cytomegalovirus.EMBO molecular medicine · 2023Article
- M-CSF directs myeloid and NK cell differentiation to protect from CMV after hematopoietic cell transplantation.EMBO molecular medicine · 2023Article
- CD150-dependent hematopoietic stem cell sensing of Brucella instructs myeloid commitment.The Journal of experimental medicine · 2023Article
- Exploiting antifungal immunity in the clinical context.Seminars in immunology · 2023Review
- Transitional premonocytes emerge in the periphery for host defense against bacterial infections.Science advances · 2022Article
- COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects.Angiogenesis · 2021Review
- Cytokine and Chemokine Responses in Invasive Aspergillosis Following Hematopoietic Stem Cell Transplantation: Past Evidence for Future Therapy of Aspergillosis.Journal of fungi (Basel, Switzerland) · 2021Review
- Granulocyte colony-stimulating factor acts on lymphoid-biased, short-term hematopoietic stem cells.Haematologica · 2021Article
- Stable colony-stimulating factor 1 fusion protein treatment increases hematopoietic stem cell pool and enhances their mobilisation in mice.Journal of hematology & oncology · 2021Article
- ZhenQi FuZheng formula-mediated improvement of hematopoietic function in cyclophosphamide-treated mice via the upregulation of macrophage colony-stimulating factor concentrations.Clinical and translational medicine · 2020Article
- Immunomodulation for the Treatment of Fungal Infections: Opportunities and Challenges.Frontiers in cellular and infection microbiology · 2020Review
- Innate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response.Frontiers in immunology · 2020Review
- Aspergillus fumigatus and Aspergillosis in 2019.Clinical microbiology reviews · 2019Review
- Menacing Mold: Recent Advances in Aspergillus Pathogenesis and Host Defense.Journal of molecular biology · 2019Review
- Hematopoietic progenitor cells as integrative hubs for adaptation to and fine-tuning of inflammation.Nature immunology · 2019Review
- Effects ofPeerJ · 2019Article
- Immunomodulation as a Therapy forJournal of fungi (Basel, Switzerland) · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Myeloablative treatment preceding hematopoietic stem cell (HSC) and progenitor cell (HS/PC) transplantation results in severe myeloid cytopenia and susceptibility to infections in the lag period before hematopoietic recovery. We have previously shown that macrophage colony-stimulating factor (CSF-1; M-CSF) directly instructed myeloid commitment in HSCs. In this study, we tested whether this effect had therapeutic benefit in improving protection against pathogens after HS/PC transplantation. M-CSF treatment resulted in an increased production of mature myeloid donor cells and an increased survival of recipient mice infected with lethal doses of clinically relevant opportunistic pathogens, namely the bacteria Pseudomonas aeruginosa and the fungus Aspergillus fumigatus M-CSF treatment during engraftment or after infection efficiently protected from these pathogens as early as 3 days after transplantation and was effective as a single dose. It was more efficient than granulocyte CSF (G-CSF), a common treatment of severe neutropenia, which showed no protective effect under the tested conditions. M-CSF treatment showed no adverse effect on long-term lineage contribution or stem cell activity and, unlike G-CSF, did not impede recovery of HS/PCs, thrombocyte numbers, or glucose metabolism. These results encourage potential clinical applications of M-CSF to prevent severe infections after HS/PC transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.